YUNYING Medicine
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
YUNYING Medicine - overview
Established
2015
Location
Shanghai, -, China
Primary Industry
Healthcare
About
Based in Shanghai, China and founded in 2015, Zhejiang Yunying Medical Technology Co. , Ltd. , trading as YINYING Medicine, operates as a healthcare company which focuses on molecular diagnosis of cancer. It has sub-branch offices in Jiaxing, Qinghai, and Gansu.
The founder and CEO of the company, Daoyun Zhang, graduated from Johns Hopkins University. The co-founder and CTO of the company, Ziying Gong, graduated from the Chinese Academy of Sciences. The company acquired certifications such as GMP Certificate and High-tech enterprise certification. In March 2026, YUNYING Medicine raised Series B+ funding led by Cufe Rising Union.
The company mainly provides tumor gene testing services, which are based on AllNGS™, Alldetect™, and DNAplus™ technologies. AllNGS™ is high specific liquid phase intersection capture technology. DNAplus™ is a plasma free DNA extraction technology used in early tumor screening, immunotherapy decision-making, etc. Yunying Medical has also developed oncolytic virus drugs for pancreatic cancer, colorectal cancer, B-cell lymphoma and melanoma.
The company also provides DNA storage tubes, DNA extraction reagents, probe products and other products. The company generates revenue by providing tumor gene testing services, oncolytic virus drugs, and other related products. The Series B+ funding raised in March 2026 will be used to further accelerate the company's layout in the field of personalized molecular diagnostics for tumors and related reagent R&D.
Current Investors
Kaitai Capital, Changsha Puwan Biotechnology, Jintan Capital
Primary Industry
Healthcare
Sub Industries
Biotechnology, Diagnostic, Medical & Imaging Laboratories, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.yymedicine.com
Verticals
HealthTech, Manufacturing
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.